Elcelyx Therapeutics

Elcelyx Therapeutics

A company that develops products for weight management and obesity-related metabolic disorders

Elcelyx Therapeutics is a biotechnology company developing products for weight management and obesity-related metabolic disorders that is headquartered in San Diego, California and was founded in 2010 by Alain D. Baron.

Funding

Series A

On March 17, 2010 Elcelyx Therapeutics completed their series A funding round with $1.2 million in funding from undisclosed investors.

Series B

On August 13, 2012 Elcelyx Therapeutics completed their series B funding round with $4 million in funding from Morgenthaler Ventures, Kleiner Perkins Caufield & Byers, and Technology Partners.

Series C

On February 24, 2014 Elcelyx Therapeutics completed their series C funding round with $20 million in funding from Technology Partners, Morgenthaler Ventures, Kleiner Perkins, and GMS Fund.

Series D

On February 23, 2015 Elcelyx Therapeutics completed their series D funding round with $5.8 million in funding from undisclosed investors.

Series E

On October 5, 2015 Elcelyx Therapeutics completed their series E funding round with $40 million in funding from Sailing Capital (lead investor), Clough Capital Partners, Morgenthaler Ventures, Kleiner Perkins Caufield & Byers, Technology Partners, and GSM Fund.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Elcelyx Therapeutics Series B round
Series B round
4,000,000
August 13, 2012
Kleiner Perkins Caufield & Byers
Elcelyx Therapeutics Series C round
Series C round
20,000,000
February 14, 2013
Kleiner Perkins Caufield & Byers
Elcelyx Therapeutics Series A round
Series A round
1,200,000
March 17, 2010
3 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.